Narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden muscle weakness (cataplexy), affects approximately 12.6/100,000 individuals with Type 1 and 25.1/100,000 with Type 2. Current narcolepsy therapeutic products, including stimulants and wake-promoting agents, address symptoms but fail to target underlying causes, leaving a high unmet clinical need for better treatment options. The narcolepsy pipeline analysis by Expert Market Research offers insights into the growing focus on innovative narcolepsy therapeutics, including orexin receptor agonists and gene therapies, is expected to drive pipeline growth in the coming years. Advancements in narcolepsy drugs aim to improve disease management, enhance patient outcomes, and offer hope to those living with this debilitating condition.
Major companies involved in the narcolepsy pipeline drugs market include Jazz Pharmaceuticals, Alkermes, Inc., and others.
Leading drugs currently in the pipeline include JZP258, TAK-861, and others.
The increasing research into orexin-based therapies, advancements in gene therapy, rising awareness, and a strong focus on addressing the significant unmet clinical need for effective treatments are likely to positively impact the narcolepsy pipeline landscape.
The Narcolepsy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into narcolepsy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for narcolepsy. The narcolepsy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The narcolepsy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with narcolepsy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to narcolepsy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles, often linked to hypocretin (orexin) deficiency. It manifests as excessive daytime sleepiness, cataplexy, sleep paralysis, and disrupted nighttime sleep. The evolving narcolepsy drug pipeline focuses on innovative therapies, including orexin receptor agonists, gene therapies, and monoclonal antibodies, to address underlying causes and improve symptom control.
Narcolepsy treatments aim to manage symptoms rather than cure the condition. Current therapies include stimulants to combat daytime sleepiness, antidepressants to control cataplexy, and sodium oxybate for both symptoms. Recent research has advanced into orexin-based therapies, targeting the disease's root cause. Personalized approaches and improved therapeutic options are emerging to enhance patient outcomes, offering hope for more effective disease management. In June 2024, Harmony Biosciences received U.S. Food and Drug Administration approval for WAKIX® (pitolisant) tablets to treat excessive daytime sleepiness in pediatric patients aged six years and older with narcolepsy. This marks the first non-scheduled, FDA-approved treatment for this population. The approval follows a priority review of a Phase 3 study conducted by Bioprojet.
According to studies, narcolepsy affects 25 to 50 per 100,000 people worldwide, with an estimated 37.7 per 100,000 individuals in the United States, translating to approximately 126,191 people. A 2022 study indicated that 47 per 100,000 individuals in Europe are affected, while the prevalence in Germany ranges from 3.1 to 9.1 per 100,000. These figures highlight the growing demand for effective narcolepsy therapeutics.
This section of the report covers the analysis of narcolepsy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The narcolepsy drug pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
The narcolepsy therapeutic assessment covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II and phase III cover a major share of the total narcolepsy clinical trials. Phase II holds the largest share at 46%, highlighting strong clinical advancements in narcolepsy treatments. Phase III follows with 40%, reflecting promising late-stage developments. Phase IV accounts for 13%, ensuring post-market safety and efficacy. Phase I contributes 7%, fostering innovations. These advancements drive market growth, improving treatment options and patient outcomes.
The drug molecule categories covered under the narcolepsy pipeline analysis include small molecules, biologics, gene therapies, and peptides. The narcolepsy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for narcolepsy. Orexin receptor agonists are emerging as a promising drug class in the narcolepsy market. TAK-861, an investigational oral orexin receptor 2 (OX2R) selective agonist, is being evaluated for narcolepsy type 1 (NT1) and type 2 (NT2). Additionally, TAK-360, another OX2R agonist, is in early-stage trials for NT2 and idiopathic hypersomnia, aiming to improve sleep-wake regulation.
The EMR report for the narcolepsy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed narcolepsy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in narcolepsy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for narcolepsy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of narcolepsy drug candidates.
Takeda is sponsoring a Phase 3 clinical trial to evaluate the efficacy and safety of TAK-861 in treating Narcolepsy Type 1 (with cataplexy). The study aims to assess improvements in excessive daytime sleepiness, cataplexy, and quality of life. Approximately 152 participants will be enrolled and the trial is expected to conclude by May 2026.
The CRYSTAL-1 study, sponsored by Centessa Pharmaceuticals (UK) Limited, aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ORX750 in treating narcolepsy and idiopathic hypersomnia. This Phase 2a, double-blind, placebo-controlled trial began on December 23, 2024, with around 78 participants enrolled. The study is anticipated to conclude by December 2025, advancing narcolepsy therapeutics.
Eisai Inc. is sponsoring a Phase 1 study to evaluate the efficacy, safety, and tolerability of E2086 compared to placebo and active comparator in adults with narcolepsy type 1. The objective is to assess its impact on excessive daytime sleepiness via the Maintenance of Wakefulness Test (MWT). The study, which will involve an estimated 40 participants, is expected to conclude by February 14, 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Narcolepsy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for narcolepsy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into narcolepsy collaborations, regulatory environments, and potential growth opportunities.
Global Narcolepsy Drugs Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share